ArticleClinical pharmacology and therapeutics2026

Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.

Rajesh KrishnaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.